Rhumbline Advisers 13F: Adds $4.2M to ARWR Stake

Rhumbline Advisers recently boosted its stake in Arrowhead Pharmaceuticals, Inc. (NasdaqGS: ARWR), increasing its holdings by 14.8%. The fund added 52,041 shares, bringing its total to 404,436 shares, valued at approximately $33.2 million as of the latest Form 13F filing with the SEC.

What Changed in Rhumbline Advisers' Arrowhead Pharmaceuticals Position

Rhumbline Advisers increased its position in Arrowhead Pharmaceuticals by 14.8%, adding 52,041 shares. This brings its total holdings to 404,436 shares, valued at $33.2 million. Prior to this, the fund held 352,395 shares.

Other Institutional Activity in Arrowhead Pharmaceuticals

BlackRock, Inc. reduced its holdings in Arrowhead Pharmaceuticals by 3,157,063 shares, now holding 18,161,519 shares valued at about $1.14 billion. Avoro Capital Advisors LLC slightly increased its stake by 74,999 shares, ending with 10,699,999 shares worth approximately $670.9 million. FMR LLC grew its holdings by 746,244 shares to a total of 7,266,652 shares, valued at around $455.6 million. Vanguard Portfolio Management LLC opened a new position with 7,146,136 shares valued at $448.1 million. State Street Corp added 92,300 shares, bringing its total to 6,496,130 shares worth $407.3 million.

Arrowhead Pharmaceuticals, Inc. Stock Up 22.6%

Shares of Arrowhead Pharmaceuticals traded near $82.00 on Tuesday. The company has a market cap of $11.55 billion and a forward P/E ratio of -18.91, indicating it is not profitable. The stock's 52-week range has been between $14.30 and $84.55, with a 50-day moving average of $74.14 and a 200-day moving average of $58.12. Arrowhead maintains a current ratio of 6.23 and a quick ratio of 6.09, with a debt-to-equity ratio of 231.05.

Recent Earnings

Arrowhead Pharmaceuticals reported revenue of $622 million, although it experienced a revenue decline of 86.4%. The company's net margin is -48.38% with a return on equity of -42.37%. The next earnings report is expected on August 6, 2026.

Insider Buying and Selling at Arrowhead Pharmaceuticals, Inc.

Recent insider activity at Arrowhead Pharmaceuticals includes several planned sales. Lu Hongbo sold 2,970 shares at an average price of $76.88 on May 12, 2026. Chief Medical Officer James Hamilton sold 10,000 shares at $75.00 on April 23, 2026, and another 10,000 shares at $64.19 on March 5, 2026. Chief Financial Officer Daniel Joseph Apel sold 13,095 shares at $71.35 on April 22, 2026. Meanwhile, COO Patrick O'Brien made a significant purchase of 75,000 shares on January 6, 2026.

Analysts Set New Price Targets

On June 17, 2026, Leerink Partners maintained a 'hold' rating with a $72.00 price target for Arrowhead Pharmaceuticals. Bernstein also maintained a 'hold' rating with a $46.00 target on May 13, 2026. RBC Capital continued its 'buy' rating with an $87.00 target on May 8, 2026, while JP Morgan initiated coverage with a 'buy' rating and an $88.00 target on May 1, 2026. The consensus among analysts remains a 'buy', with an average target price of $89.08.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biotechnology company based in Pasadena, California. It focuses on developing medicines for treating intractable diseases. The company has a strong pipeline of RNAi-based therapeutics targeting various conditions, including cardiovascular and metabolic diseases. Arrowhead collaborates with several major pharmaceutical companies, including GlaxoSmithKline, Takeda, Amgen, and Sarepta Therapeutics. Founded in 2003, the company is led by CEO Dr. Christopher R. Anzalone and employs around 711 people.

Bottom Line

Rhumbline Advisers' increased stake in Arrowhead Pharmaceuticals reflects continued interest from institutional investors. The company's stock performance and analyst ratings suggest a focus on its developmental pipeline and strategic partnerships. As always, remember that 13F filings are backward-looking and may not reflect current positions.